Prostate cancer — all decisions

The Board denied the Veteran's claim for service connection for prostate cancer, finding that the evidence does not support a causal relationship between the condition and his active military service.

The Board remands the claim for service connection for prostate cancer due to pre-decisional errors in the July 2024 rating decision and medical opinion.

The Board dismissed the claims for service connection for erectile dysfunction, prostate cancer, and a bladder disability due to an impermissible concurrent election under the modernized review system.

The Board granted service connection for prostate cancer and erectile dysfunction, with the latter being secondary to the former.

The Board remands the appeal for a TERA opinion to determine if the Veteran's in-service exposures caused his prostate cancer.

The Board denied the Veteran's claim for service connection for prostate cancer, finding that there was no credible evidence of exposure to herbicide agents and no indication that the condition began in or is related to service.

The Board denied service connection for a right shoulder disability, bilateral hearing loss, tinnitus, prostate cancer, a disability manifested by lower extremity numbness, and vertigo due to the lack of evidence showing these conditions were incurred in or aggravated by active service.

The Board remands the service connection claim for prostate cancer to correct a duty to assist error related to the Veteran's toxic exposure risk activity (TERA) and the lack of an Individual Longitudinal Exposure Record (ILER).

The Board denied service connection for benign prostatic hyperplasia (BPH) with incontinence, urinary frequency and erectile dysfunction, also claimed as prostate cancer.

The Board granted service connection for hypertension, prostate cancer, and multiple myeloma based on their direct relationship to the Veteran's active duty service.

The Board denied the veteran's claim for an initial rating in excess of 0 percent for prostate cancer residuals, as the evidence did not support a higher rating.

The Board denied a compensable rating for residuals of prostate cancer and a rating in excess of 10 percent for hypertension.

The Board remands the claim for a higher rating for prostate cancer residuals to correct a pre-decisional duty to assist error.

The Board remands the claim for service connection of prostate cancer due to exposure to certain toxic chemicals, including Agent Orange, as there were pre-decisional errors in the development of the claim.

The Board remands the claims for service connection for prostate cancer, multiple myeloma, and related conditions as they are inextricably intertwined with the claim for service connection for multiple myeloma.

The Board granted earlier effective dates for service connection and related benefits, including prostate cancer, erectile dysfunction, special monthly compensation, and DEA benefits, all effective May 10, 2022.

The Board remands the claim for service connection for prostate cancer due to pre-decisional errors in the July 2024 rating decision and medical opinion.

The Board remands the Veteran's claims for service connection for dementia, PACT Act related disorders, and peripheral neuropathy due to a need for additional medical examinations.

The Board granted an initial 10 percent rating for residuals of prostate cancer prior to January 19, 2024, and a 20 percent rating from that date. Service connection was also granted for erectile dysfunction, and special monthly compensation based on loss of use of a creative organ was awarded.

The Board remands the claims for service connection for prostate cancer, diabetes, and hypertension to obtain additional evidence regarding in-service toxic exposures.